ENGN: Detalimogene achieves strong efficacy and safety in NMIBC, targeting a $20B+ market
Detalimogene, a non-viral gene therapy for NMIBC, shows a 54% complete response rate and favorable safety in pivotal trials, with streamlined administration and strong community practice fit. Surfactant addition may further boost efficacy. Market opportunity exceeds $20B, with key regulatory milest…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.